These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 27799565)
1. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565 [TBL] [Abstract][Full Text] [Related]
2. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process. Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis. Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
5. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485 [TBL] [Abstract][Full Text] [Related]
6. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
8. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements. Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069 [TBL] [Abstract][Full Text] [Related]
9. Sphingosine Induces Apoptosis and Down-regulation of Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758 [TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation. Xie Z; Tang Y; Su X; Cao J; Zhang Y; Li H RNA Biol; 2019 Jan; 16(1):144-153. PubMed ID: 30593263 [TBL] [Abstract][Full Text] [Related]
12. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562 [TBL] [Abstract][Full Text] [Related]
13. PAX3-FOXO1: Zooming in on an "undruggable" target. Wachtel M; Schäfer BW Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205 [TBL] [Abstract][Full Text] [Related]
14. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931 [TBL] [Abstract][Full Text] [Related]
15. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155 [TBL] [Abstract][Full Text] [Related]
16. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
17. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
18. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785 [TBL] [Abstract][Full Text] [Related]
19. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014 [TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]